Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.

Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, Iizasa T, Nakayama T, Taniguchi M, Fujisawa T.

Clin Cancer Res. 2005 Mar 1;11(5):1910-7.

2.

A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.

Motohashi S, Ishikawa A, Ishikawa E, Otsuji M, Iizasa T, Hanaoka H, Shimizu N, Horiguchi S, Okamoto Y, Fujii S, Taniguchi M, Fujisawa T, Nakayama T.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6079-86. Epub 2006 Oct 6.

3.

A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.

Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, Hanaoka H, Shimizu N, Suzuki M, Yoshino I, Taniguchi M, Fujisawa T, Nakayama T.

J Immunol. 2009 Feb 15;182(4):2492-501. doi: 10.4049/jimmunol.0800126.

4.

Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma.

Kunii N, Horiguchi S, Motohashi S, Yamamoto H, Ueno N, Yamamoto S, Sakurai D, Taniguchi M, Nakayama T, Okamoto Y.

Cancer Sci. 2009 Jun;100(6):1092-8. doi: 10.1111/j.1349-7006.2009.01135.x. Epub 2009 Mar 11.

5.

A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.

Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, von Blomberg BM, Scheper RJ, van der Vliet HJ, van den Eertwegh AJ, Roelvink M, Beijnen J, Zwierzina H, Pinedo HM.

Clin Cancer Res. 2002 Dec;8(12):3702-9.

6.

[Translational research in patients with lung cancer--clinical application of NKT cell immunotherapy].

Motohashi S.

Gan To Kagaku Ryoho. 2007 Apr;34(4):550-3. Japanese.

PMID:
17431340
7.

Human peripheral blood Valpha24+ Vbeta11+ NKT cells expand following administration of alpha-galactosylceramide-pulsed dendritic cells.

Okai M, Nieda M, Tazbirkova A, Horley D, Kikuchi A, Durrant S, Takahashi T, Boyd A, Abraham R, Yagita H, Juji T, Nicol A.

Vox Sang. 2002 Oct;83(3):250-3.

PMID:
12366768
8.

A set of genes associated with the interferon-γ response of lung cancer patients undergoing α-galactosylceramide-pulsed dendritic cell therapy.

Okita K, Motohashi S, Shinnakasu R, Nagato K, Yamasaki K, Sato Y, Kitamura H, Hijikata A, Yamashita M, Shimizu K, Fujii S, Ohara O, Taniguchi M, Sakaida I, Nakayama T.

Cancer Sci. 2010 Nov;101(11):2333-40. doi: 10.1111/j.1349-7006.2010.01696.x.

9.

Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide.

Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M.

J Immunol. 1999 Sep 1;163(5):2387-91.

10.

Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer.

Uchida T, Horiguchi S, Tanaka Y, Yamamoto H, Kunii N, Motohashi S, Taniguchi M, Nakayama T, Okamoto Y.

Cancer Immunol Immunother. 2008 Mar;57(3):337-45. Epub 2007 Aug 10.

PMID:
17690880
11.

Comparison of clinical and immunological effects of intravenous and intradermal administration of α-galactosylceramide (KRN7000)-pulsed dendritic cells.

Nicol AJ, Tazbirkova A, Nieda M.

Clin Cancer Res. 2011 Aug 1;17(15):5140-51. doi: 10.1158/1078-0432.CCR-10-3105. Epub 2011 Jun 8.

12.

Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15.

van der Vliet HJ, Nishi N, Koezuka Y, von Blomberg BM, van den Eertwegh AJ, Porcelli SA, Pinedo HM, Scheper RJ, Giaccone G.

J Immunol Methods. 2001 Jan 1;247(1-2):61-72.

PMID:
11150537
13.
14.

Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients.

Motohashi S, Kobayashi S, Ito T, Magara KK, Mikuni O, Kamada N, Iizasa T, Nakayama T, Fujisawa T, Taniguchi M.

Int J Cancer. 2002 Nov 10;102(2):159-65. Erratum in: Int J Cancer. 2003 May 10;104(6):799.

15.

Dendritic cells are targets for human invariant Valpha24+ natural killer T-cell cytotoxic activity: an important immune regulatory function.

Nicol A, Nieda M, Koezuka Y, Porcelli S, Suzuki K, Tadokoro K, Durrant S, Juji T.

Exp Hematol. 2000 Mar;28(3):276-82.

PMID:
10720692
16.

Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells.

van der Vliet HJ, Molling JW, Nishi N, Masterson AJ, Kölgen W, Porcelli SA, van den Eertwegh AJ, von Blomberg BM, Pinedo HM, Giaccone G, Scheper RJ.

Cancer Res. 2003 Jul 15;63(14):4101-6.

17.

Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs.

Osada T, Morse MA, Lyerly HK, Clay TM.

Int Immunol. 2005 Sep;17(9):1143-55. Epub 2005 Jul 18.

PMID:
16027139
18.

In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma.

Kikuchi A, Nieda M, Schmidt C, Koezuka Y, Ishihara S, Ishikawa Y, Tadokoro K, Durrant S, Boyd A, Juji T, Nicol A.

Br J Cancer. 2001 Sep 1;85(5):741-6.

19.

Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.

Fujii S, Shimizu K, Hemmi H, Steinman RM.

Immunol Rev. 2007 Dec;220:183-98. Review.

PMID:
17979847
20.

The effects of alphaGalCer-induced TCRValpha24 Vbeta11(+) natural killer T cells on NK cell cytotoxicity in umbilical cord blood.

Ueda Y, Hagihara M, Gansuvd B, Yu Y, Masui A, Okamoto A, Higuchi A, Tazume K, Kato S, Hotta T.

Cancer Immunol Immunother. 2003 Oct;52(10):625-31. Epub 2003 Jun 12.

PMID:
12802518

Supplemental Content

Support Center